Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hemodialysis in Children DR. KHALID AL-ALSHEIKH MD Director of Nephrology & Dialysis Center Consultant Pediatric Nephrologist AFHSR, Khamis Mushayt, KSA.

Similar presentations


Presentation on theme: "Hemodialysis in Children DR. KHALID AL-ALSHEIKH MD Director of Nephrology & Dialysis Center Consultant Pediatric Nephrologist AFHSR, Khamis Mushayt, KSA."— Presentation transcript:

1 Hemodialysis in Children DR. KHALID AL-ALSHEIKH MD Director of Nephrology & Dialysis Center Consultant Pediatric Nephrologist AFHSR, Khamis Mushayt, KSA

2 Introduction In children with chronic kidney disease as GFR declines to less 30ml/min/1.73 m2 ( Stage 4 CKD) Preparation for renal replacement therapy are needed. The child and his family should be provided with information related to preemptive kidney transplantation Peritoneal dialysis Hemodialysis Renal replacement therapy is initiated in children with CKD stage 5 in some children with CKD stage 4 Hemodialysis in children progress over last 20 years Morbidity of the session has decreased Technological progress, the availability of ESA and GH enhanced dialysis dose and increase quality of life Technically all children can underwent HD even infants 2

3 Indication of RRT Renal function, ?GFR Before uremic symptoms Fluid status Biochemical abnormalities Acute renal failure Oligoanuric Resistant volume overload to medical treatment Hyperkalamia resistant to medical treatment Persistent metabolic acidosis resistant to medical treatment Uremic encephalopathy Uremic pericarditis Inborn error of metabolism Intoxication 3

4 Incidence of ESRD in Children ESRD in children is uncommon Incidence in USA 14.8 / Million New Zealand 13.6 / million Japan 4 / million The choice of RRT children: ¼ underwent preemptive renal transplantation ½ started in peritoneal dialysis ¼ started in hemodialysis Preemptive kidney transplantation which is performed prior to the need of dialysis. Renal transplantation is associated with better quality of life (Growth and Development) 4

5 Pediatric Dialysis in Saudi Arabia HD Patients above 75 years and below 15 years of age 2012 Below 15 years 223 (1.8%) 15-75 11739 (91.4%) Above 75 878 (6.8%) PD patients adult and children 2012 Children 172/1327 = 13% Adults 1155/1327 = 87% SCOT Annual Report 2012 5

6 Epidemiology of chronic kidney disease in children Pediatr Nephrol (2012) 27:363–373 و Jérôme Harambat & Karlijn J. van Stralen &Jon Jin Kim & E. Jane Tizard 6

7 Chronic Renal failure in children in Asir Region of Saudi Arabia N. Alharbi Saudi Journal of Kidney Disease and Transplantation 1997 V8 Issue 3 pp 294-297 7

8 Chronic Renal failure in children in Western Area of Saudi Arabia Jameela A. Kari Saudi Journal of Kidney Disease and Transplantation year 2006 V17 Issue I pp 19-24 8

9 9

10 Comparison of RRT Modalities in Children 10

11 Choices of Dialysis When preemptive transplantation is not an option the choices between the two forms of dialysis is generally dictated by patients age, technical, social, compliance issues and family preference. 11

12 12

13 Principle of Vascular Access Deliver adequate flow rate Has long use life Has low rate of complications - Infection - Stenosis - Thrombosis - Aneurysm - Limb ischemia 13

14 The best is AVF USA - CVC used most often more than AVF and graft - CVC  89% For children<13 Years 64% 13-19 YEARS Review of 2006 annual reports (NAPRTCS) reveals that in a family of pediatric patients 78.9% receiving HD have CVC as primary access. AVF 12.3% AVG 8.5% 14

15 AV Fistula con’t. PREFERRED SITE FOR AVF IN CHILDREN 1.Radiocephalic 2.Brachiocephalic 3.Brachiobasilic with or without transposition Alternative: -Ulnar artery to basilic vein -Femoral artery to saphenous vein -Nondominant forearm 15

16 Definite guidelines regarding minimal vessel sites don’t exist General consensus preferred of minimum 2.5 mm venous diameter Doppler U/S scanning or venography can provide information regarding adequate: A) vessel size B) venous stenosis 16

17 AVG AVG Should be considered an option for HD access in children especially who require replacement of native vessels to perform an adequate anastamosis Alternative materials: 1.Saphenous vein 2.Bovine 3.Umbilical 4.Darcon 5.Polyurethane, cryopreserved femoral vein 6.Polytetrafluorethylene (PTFE) is most commonly used 17

18 One study compare bovine with PTFE graft demonstrated fewer complications with PTFE ones: - Lower infections - Lower thrombosis - Easier to obtain and easier to repair Graft are most commonly placed in forearm between brachial artery & basilic to brachial vein. The thigh can be used femoral artery and saphenous to femoral vein in small children -Higher infection rates been noted with thigh graft than with upper extremity grafts 18

19 Advantage of AVG 1.Shorter time to use 2.High primary potency rate 3.Ease of technical creation Sheath et al reported creation of 24 AVF and 28 AVG respectively. The most common site of AVG is the thigh -50% of patients Disadvantages of AVG 1.Thrombosis 2.Stenosis 3.Infection Sheath et al permanent vascular access survival in children and adolescent with end stage renal disease 2002 Kidney Int 62:1864-1869 19

20 Ramage et al reported long term complications rate of AVF compare with AVG in retrospective study conducted over 20 years - Intervention rate 17.8% AVF compared to 33% of AVG Reason of discontinuation of AVG were: 1. Infection 20% 2. Thrombosis 73% Chant et al evaluated dialysis adequacy, KT/V, URR, anemia management and albumin status based on vascular access. No difference between AVF & AVG Possible Complications of graft 1. Thrombosis 2. Stenosis 3. Infection 4.Steal syndrome Ramage et al Vascular access survival in children and young adults receiving long term hemodilaysis 2005 AJKD 45:708-714 Chant et al Comparison of vascular access type for pediatric HD with respect to urea clearance, anemia management, & serum albumin conc. 2005 AJKD 45:303-308 20

21 COMPARISON BETWEEN AVF & AVG AVFAVG Lower infectionHigher infection Lower thrombosis rateHigher thrombosis rate May take 3-6 months to matureCan be use within few weeks Primary Failure rate is higherPrimary Failure is lower Secondary Failure rate is lowerSecondary Failure rate is higher 21

22 CENTRAL VENOUS CATHETER Central venous catheter are the most commonly used vascular access in children in north America data from USRDS 40% of children who were receiving chronic HD continued to use catheter Data from ANZDATA 2008 showed the catheters were used exclusively below 10 years of age NAPRTCS 2008 78% catheters 12% AVF 7% AVG European Pediatric Dialysis Working Group 60% catheters 38% AVF 2%AVG 22

23 CENTRAL VENOUS CATHETER First choice in patient require urgent HD 2. Stage V CKD 3. As abridge from a patient who is expected to receive planned transplant 4. Is training to transfer to PD -Advantage - It can be used immediately -Disadvantage 1. Short life span 2. Thrombosis 3.Infection 4. Malfunction 5. Possible fibrin sheath formation -Median survival times of CVC is 4 months – 10.6 months 23

24 CENTRAL VENOUS CATHETER Goldstein et al evaluated catheter survival time in 58 uncuffed & 22 cuffed CVCs Median survival time of uncuffed catheter is 31 days and cuffed catheter is 123 days 1 year survival of long term cuffed catheter 27% CVC in children whose vasculature is too small <10 kg, CVC may be the best temporary solution Goldstein et al 1997 HD catheter survival and complications in children and adolescent pediatric nephrology 11: 74-77 24

25 Two questions to be answered: What size of catheter to use? Where to put it? 25

26 “SIZE MATTERS!”

27 Pousielle’s law- Smaller diameters offer greater resistance to flow Longer lengths offer greater resistance to flow Decreasing the diameter by 1/5th is the same as doubling the length (roughly a 2 French size difference) Q = ∆Pπr 4 8  l 27

28 Catheter Specifications French Size 5781012 Flow Rate (ml/min) ?80-100150-200250-300285-330 28

29 Catheter Specifications French Size 5781012 Diameter (mm) 1.672.32.73.34.0 29

30 Vascular Access Central Venous catheter Cuffed catheter Uncuffed catheter sizeWeighttype 8Up to 20Uncuffed catheter dual lumen 1020-30 11.5Above 30 720-40Tesio Catheter 1040-60 12Above 60 1020-40Ash Split 30

31 Complications of CVC USRDS data have shown sepsis rate with CVCs approximate 80/100 patient as compared to 10/100 patient for AVF Potential sequences of CVC include: - Septic shock - Subacute bacterial endocarditis - Osteomyelitis - Epidural abscess One study evaluated potential differences in infection rate based on use of three agents for exit site care - 2% chlorhexidine found infection rate is 0.5% - 10% povidine iodine found infection rate is 2.5% - 70% alcohol found infection rate is 2.3% Different antimicrobial catheter lock studies suggest that citrate is ideal 31

32 PROS AND CONS OF CENTRAL VENOUS CATHETER FOR HD IN CHILDREN PROSCONS Easily placedInfection rate high Can be use immediatelyFailure rate and replacement rate high Painless to the patientBlood flow rates are variable Require little planning prior to placementPermanent damage to central venous system (stenosis/thrombosis) Easily removed if used as transitional access for future PD on transplant patients Damage to central vessels can prohibit future AVF/AVG placement in ipsilateral extremity No vascular StealPossible arrythmia Decreased risk of high outpatient cardiac failure 32

33 Monitoring of vascular access Goldstein et al described use of dilution technique on regular basis on pediatric patient population to date improve the life of access. Use of ultrasound 50% reduction in number of hospitalized patient. This further supported by NFK/K-DOQI guidelines for pediatric vascular access. Based on review of current literature the authors would propose the following as tools for ongoing monitoring of AVFs and AVGs. 33

34 Access Monitoring 1. Inspection: the access should be assessed weekly through inspection, palpation, and auscultation by the nursing staff. - With specific attention to arm swelling. - Prolonged bleeding after needle removal. - Change in thrills or bruits. -The nephrologist should inspect the access at each physical examination. 2. Surveillance ↓KT/V or URR. Determination of access recirculation should be documented on a monthly basis. Ultrasound dilution/month if not available do Doppler U/S /month. 34

35 Access Monitoring 3. Referral: Fistulogram with possible angioplasty if: - Inadequate blood flow comprising adequacy. - Elevate access recirculation >20% after needle connection. - Corrected access flow less than 650ml/min/1.73m2 by U/S dilution. - Consistent abnormality on Doppler U/S. -Pseudoaneurysm has formed, rotation of puncture site can help minimize risk of pseudoaneurysm. 35

36 Hemodialysis Prescription Hemodialysis Equipment: Tubing Dialyzer Dialysis Machine Tubing: TotalArterial (ml)Venous (ml)Pt. weightTubing 29821<6 kgMini Neonatal 4018226-12 kgNeonatal 723042>12 kgPediatric 1326070>30 kgAdult 36

37 Types of Dialyzer Dialyzer: Types of Membrane Blood volume capacity Service area UF coefficient Clearance of various substances Sterilization 37

38 Hemodialysis Prescription Types of Dialyzer Low flux (KUF <10 ml/hr/mmHg) High flux KUF 15-60 ml/mmHg Hallow fiber (capillary) Parallel Plate Types of Membranes Unmodified cellulose low flux Modified cellulose (Low & high flux) Synthetic (low & high flux) Synthetic noncellulose membranes are more biocompatible, size of dialyzer shouldn’t exceed 75-100% of patient service area 38

39 Selection of Dialyzer that can be used in children DialyzerSurface Area (m 2 ) Fill Volume (ml) UF Coefficient (ml/min/mmHg) Gambro Polyflux 14L1.3779.5 Polyflux 17L1.710312.5 Polyflux 11S1.18153 Polyflux 14S1.410262 Polyflux 17S1.712171 2H (HF)0.21715 6H (HF)0.65233 Fresenius F30.4281.7 F4 HPS0.7424.3 F5 HPS1.0636.2 F6 HPS1.3828.5 F7 HPS1.61029.8 F8 HPS1.811411.1 Xenium 110 (HF)1.16949 130 (HF)1.37862 150(HF)1.59163 210(HF)2.112680 Baxter CA-50 (LF)0.5352.5 FB 110GA1.1658.1 39

40 Hemodialysis Prescription con’t. Dialysis Machine: Precise control of UF, volumetric assessment Capable of low blood flow speeds Ability to use lines of varying blood volume Measure removal of very small amount of fluids Continuous blood volume monitoring 40

41 Hemodialysis Prescription Blood Flow rate 1 st session 90 ml/m 2 2-3 ml/kg/min Latter 5-7 ml/kg/min 150-200 ml/m 2 Dialysate: It compose Treated water Electrolytes Na 140 mmol/L, K 2-3 mmol/L. Cl 100-102 meq/L, HCO3 40 meq/L, Mg 1.5-2 meq/L, Ca 1.25-1.5 mmol/L Acid Buffers Glucose 100 g/L Dialysate Flow rate 2 times more than blood flow rate, standard 500 ml/min UF: Standard weight 1.5-2 % of BW/hr. not more than 5% BW/HD session 41

42 Hemodialysis Prescription cont. Anticoagulation Heparin loading – 2000 IU/m2 20 IU/kg 10 IU/kg in infant Maintenance – 400 IU/m2 10-20 IU/kg to be discontinued 30 minutes prior to the end of dialysis aPTT 120-160 or more than 50% above baseline of ACT Heparin lock: with concentrated heparin 50 U/kg/lumen for weight less than 10 kg 1000 U/mlBW (10-20 kg) 2500 U/mlBW>20 kg 42

43 Hemodialysis Prescription Components 43

44 Hemodialysis Adequacy Hemodialysis adequacy: Minimum adequate dose of HD given 3/times/week to patient with K r less than 2ml/min/173m 2, spkt/v 1.2/dialysis URR of 65% Target dose HD 3 times/week spkt/v 1.4/dialysis not including residual kidney function URR 70% single port kt/v 44

45 Methods of Measurement of Delivered Dose of Hemodialysis Single-pool Kt/V calculated by Daugirdas II Formula Equation I: spKt/V = - In (C1/C0 – 0.008 x t) + (4 – 3.5 x C1/C0) x UF/W Equilibrated kt/V Equation II: estBUN = ([BUN 15min – BUN 30secs ]/0.69) + BUN 30secs KDOQI Guidelines 2006 Cherry Mammen, Goldstein White Standard kt/V threshold to accurately predict single pool kt/V target for children receiving thrice weekly maintenance HD. Nephrology Dialysis Transplant 2010 45

46 Methods of Measurement of Delivered Dose of Hemodialysis Equation III: cKt/V (Goldstein) = -1n (estBUN/CO – 0.008 x t)+ (4-3.5 x estBUN/C0) x UF/W Equation IV: stdKt/V = 168 * [1-exp[-eKt/V]/t]/ [1 – exp [ - eKt/V]/spKt/V] + [168/(N * t) – 1] Equation V: URR = 100x(estBUN – BUN 30secs )/ BUN 30secs Equation VI: %UFF = 100 – [(pre-treatment weight – post-treatment weight)/post-treatment weight] Cherry Mammen, Goldstein White Standard kt/V threshold to accurately predict single pool kt/V target for children receiving thrice weekly maintenance HD. Nephrology Dialysis Transplant 2010 46

47 Recommended Methods vs Treatment Type for 2-3 HD per week For 2 or 3 dialysis Treatment per week Single pool Kt/Vurea determined by: Urea kinetic modeling Simplified multivariable equation Equilibrated Kt/V (eKt/V) Bloodless measurements of dialyzer clearance using ionic conductance or dialysate urea monitoring URR Double pool Kt/Vurea by formal kinetic modeling (used only for research purposes) Solute removal index (SRI) from dialysate collections For more frequent dialysis: a continuous equivalent of kidney clearance Standard Kt/V urea Normalized Kt/V urea 47

48 Maintaining Hemodialysis Adequacy Preservation of residual renal function Aggressive Management of HTN Avoidance of Excessive UF Avoidance of potential insults to RRF (contrast, medications, infection, volume, contraction) 48

49 Lower Kt/V causes If spKt/V is lower than expected: Blood flow rate Duration of treatment Dialysate flow Dialyzer specification and KoA Intradialytic hypotension Undetected early termination of treatment Was the anticoagulation adequate? Was post dialysis blood sampling appropriate? Was the needle size and placement appropriate and optimal? Was the blood pump adequately calibrated? Was the blood pump segment wrong? Was parenteral nutrition infused during treatment? 49

50 Practical example of hemodialysis adequa cy nPCRspKt/VWeight (kg)Month 1.201.4034.31 1.151.3235.22 1.181.2036.13 50

51 Practical example of hemodialysis adequacy nPCRspKt/VWeight (kg)Month 1.201.4034.31 0.901.3235.22 0.651.2036.13 51

52 Practical example of hemodialysis adequacy nPCRspKt/VWeight (kg)Month 1.051.4034.01 0.951.3232.52 0.881.4531.33 52

53 Anemia Management in ESRD in children Hb 11-12 g/dl Serum ferritin target level >100 mg/ml Tsat >20% Monthly (CBC & reticulocyte count) Every 3/12 serum ferritin, serum Tsat and serum iron. with change therapy CBC weekly for 6/52 53

54 Eryhtropoetin Initial dosing of HD below 5 years 250-300 unit/kg/week) Above 5 years 150-200 units/kg/week Darbapoetin 0.45 – 0.75 mcg/kg/week IF Hb above target level or increase by 1.3 g/dl in 2 weeks decrease 25% of ESA IF Hb increase 1.6-2 g/dl isn’t achieved over 8 weeks increase ESA by 25% Iron Iron dextran need test dose because of anaphylaxis Iron gluconate, sucrose. No need for test dose KDOQI Guidelines 2006 54

55 Serum phosphorus Children 1-12 years 4-6 mg/dl (1.26-1.93 mmol/L) Children over 12 years – 3.5-5.5 mg/dl (1.13-1.78 mmol/L) Serum calcium 8.8-9.5 mg/dl 2.20-2.37 mmol/L Ca x phosphate products should be less than 5 mmol/L Total eliminated Ca should not exceed 2500 mg/day Metabolic acidosis HCO 22 mmol/L Bone Mineral Management in ESRD KDOQI Guidelines 2006 55

56 Bone Mineral Management in CKD Target serum PTHGFR Range (ml/min/1.73 meter square) CKD stage 35-70 PG/ml, 3.85-7.7 pmol/l60-892 35-70 pg/ml, 3.85-7.7 pmol/l30-593 70-110 pg /ml, 7.7-12.01 pmol/l15-294 200-300pg/ml, 22-33 pmol/l<15 or dialysis5 56

57 PTH, alkaline phosphataseCalcium, PO4, total CO2GFRStage At least yearly 60-892 At least every 6 months 30-593 At least every 3 months 15-294 At least every 3 monthsAt least every month<15 or dialysis5 Bone Mineral Management in CKD 57

58 Nutritional Status Phosphorus – CKD 3 – 5 and 5D decrease dietary phosphate to 80% of DRI for age when PTH above target range of CKD and phosphate exceed normal reference Protein – dietary protein 100-140 of daily protein requirement for CKD 3-5 Carbohydrate: Normal carbohydrate compare to age match healthy child Vitamins – B1, B2, B3, B5, B6, B8, B12, vitamin C, A, K, folic acid, copper, zinc should be 100% of daily requirement Trace elements 100% if clinical evidence of deficiency Free water & Na supplementation should be consider for polyuric child. Na supplements should be consider for all infants in PD due to substantial loss even anuric and to be restricted for hypertensive child Potassium should be restricted for CKD 2-5 Acidosis is to be corrected to HCO3 22 mmol/l KDOQI Guidelines 2006 58

59 Nutritional Status Growth Growth hormone CKD 2-5 for short stature or height /age <3 rd centile persist for 3 months despite adequate nutritional treatment and correction of metabolic abnormalities Calories should be 100% maintaining its chronological age 59

60 Complications During Hemodialysis Disequilibrium symptoms – movement of water to brain cell by osmosis due to sudden drop of urea in plasma Presentation: Nausea, headache, dizziness and seizure, coma Treatment: Blood flow, dialyzer, duration of treatment Mannitol of infusion 1g/kg over 1 h 1 st session 30% drop, increase 50%, target 70-75% urea reduction Ct/C0 = e –kt/V Ct urea after t minutes of dialysis C0 urea at initiation of dialysis K – specific dialyser urea clearance ml/min V = Patient urea volume of distribution 60

61 Complications During Hemodialysi s Hypotension: Intravascular volume depletion due to slow refiling from extravascular space Use of dialysate Na lower than plasma Exchanging UF Impaired sympathetic activity Warm dialysate – vasodilation Splanching pooling of blood while eating during dialysis Use of antihypertensive medication on day of dialysis Treatment: NS 5 ml/kg Cessation of UF Reassessment of target eight daily fluid allowance review Separate UF from dialysis Na ramping Hct monitoring 61

62 Complications During Hemodialysis Intradialysis hemolysis Symptoms: Pain & nausea Presentation: Dark appearance to venous blood due to over heating, contamination, hypertonicity of dialysate, kinking of line, malfunctioning of pump Treatment: Stop dialysis, check potassium Urticaria: antihistamine or hydrocort Air embolism: rare as air detection will clamp the return line 1 ml/kg Symptoms: Seizure, coma, chest symptoms Treatment: Clamp lines, stop pump, put head down, give 100% oxygen Air may need to be aspirated from ventricles 62

63 Complication Post-Dialysis Malnutrition is common is children receiving hemodialysis. The risk of death is reported: 54% for each 1 g/dl fall in albumin 57% reduced if serum albumin >4g/dl 14% increased with each decrease of one height of standard deviation score below normal at start of dialysis Neuropsychologial outcomes: One study showed children below 18 months have: 42% neuropsychological impairment 58% attend regular school 63

64 64

65 65

66 Social & Psychological Issues Dialysis Unit Vacation School Economic status Transfer of Service 66

67 Complication Post-Dialysis Renal osteodystrophy Cardiovascular Disease Hypertension – in one case series 624 children in HD 79% of them was with hypertension and with 62% receiving antihypertensive medications Left ventricular hypertrophy up to 80% 67

68 Mortality Mortality risk in children in dialysis is >30 times higher than age and gender match normal children US 5 years survival of 2867 patient starting dialysis at age 1, 1-5, and >5 years was 60, 80, and 85% ANZATA- RRT 1963-2002 demonstrated a 10 years and 20 years survival 79% and 66%. Mortality is higher in children in dialysis and less post transplant as noted by ANZATA UK Network 10 fold higher risk of death in children on dialysis compared to those were transplanted Cause of Death is CVD 1000 fold higher in young adults on dialysis than age match normal USRDS – 22.5% of death due to CVD ANZATA 45% of death due to CVD Dutch 41% of death due to CVD 68

69 Mortality Age at start of dialysis NAPRTCS report lower survival for children who begin HD before 1 year of age with survival rate of 82, 73 63% at 1, 2, 3 years after initiation of dialysis. Comparison of survival between Hemodialysis and PD Italian registry showed no difference between 5-15 years but below 5 years who were most exclusively managed by PD had a poorer 5 years survival USRDS showed no difference in 5 years survival between PD and hemodialysis at any age 69

70 Mortality 2013 USRDS Annual Data Report, Pediatric ESRD volume 2 70

71 Mortality 2013 USRDS Annual Data Report, Pediatric ESRD volume 2 71

72 Mortality 2013 USRDS Annual Data Report, Pediatric ESRD volume 2 72

73 Mortality 2013 USRDS Annual Data Report, Pediatric ESRD volume 2 73

74 Summary of Hemodialysis in Children Although principles of hemodialysis are similar for adult and children there are fundamental differences in technical aspect of procedures and complications Optimal care is provided by multidisciplinary team (Pediatric Nephrologist, skilled nurses, dietician, vascular access coordinator, vascular surgeon, radiologist, psychologist, and social worker) Good vascular access is essential for the success of hemodialysis Hemodialysis equipment must be modified for pediatric patient Long-term quality of life is lower in children on dialysis compared with normal healthy control and children receiving renal transplant 74

75 75


Download ppt "Hemodialysis in Children DR. KHALID AL-ALSHEIKH MD Director of Nephrology & Dialysis Center Consultant Pediatric Nephrologist AFHSR, Khamis Mushayt, KSA."

Similar presentations


Ads by Google